The Phase2 trial will have limitations due to its size. We

New Post Public Reply Private Reply Replies (3) Message Board
farrell
609
The Phase2 trial will have limitations due to its size. We can expect the phase 3 trial to be much larger and more statistically accurate.

One undeniable factor in Brilacidin's favor is how mediocre the Covid19 antiviral competitors have been. Below is listed some of the concerns with Remdesivir, Regeneron's antibody therapy and Bamlanivimab.

Remdesivir is the Covid19 antiviral of choice at many hospitals in spite of its widely criticized early trial.Its "adaptive trial" was changed in mid course when it became obvious it did not improve mortality. Its only treatment benefit was a shorter hospital stay which was not an initial end point of the trial.The control group was eliminated.

"The study found that on day 11, patients in the five-day remdesivir arm were 65% more likely to achieve better clinical scores than the standard care arm. Using the same yardstick, there was no benefit with 10 days of remdesivir. Also, there was no reduction in hospitalisation, mortality or reduced duration of oxygen requirement. They concluded that patients receiving five days of remdesivir had a significantly different clinical status than those receiving standard therapy, with uncertain clinical importance.

As with previous COVID-19 related clinical trials, there are several red flags we need to address before interpreting the results. Of note: the sponsor of the trial is Gilead Sciences Inc., a major manufacturer of remdesivir. Additionally, the end-point is an unimpressive one: odds of a better clinical status is quite vague relative to other, more clinically meaningful measurements like mortality, hospital stay, duration of oxygen requirement, etc. None of the authors’ own exploratory end-points, such as time to recovery or time to improvement in clinical status (by 1, 2 or 3 points) were significantly different with remdesivir.

Of the patients included, 80-85% had a clinical score of 5 (hospitalised, not requiring supplemental oxygen but requiring ongoing medical care). It is unclear how the same end-point – change in clinical status – that was used by the trial group for their previous trials involving severe COVID-19 patients can be applied to patients with moderate disease.

At the outset, the premise of this trial is questionable at the least. Remdesivir costs Rs 5,000 per dose, implying a cost of Rs 30,000 or Rs 60,000 for a five- or 10-day course respectively. In people with moderate COVID-19, where the mortality was 1%, it is impossible to justify remdesivir’s use without evidence of concrete clinical benefit. There is nothing objectionable about negative trials – which are those trials that fail to achieve their desired end-point. However, the fact that this trial was allowed to report its result as positive, in favour of remdesivir, is highly suspect.

Also read: Remdesivir – a Drug in Search of a Disease

In a nutshell, this trial encapsulates the issues with trials funded by the pharmaceutical industry in the context of the COVID-19 pandemic. By applying an ambiguous end-point to a patient population that may not have needed any treatment other than supportive care or supplemental oxygen, this trial bears all the hallmarks of bad science. Another difficult concept to grasp is why patients receiving 10 days of remdesivir had no difference in clinical status compared to standard treatment, while those receiving five days of treatment did. Considering that all three arms had comparable characteristics and were randomised, the benefit from remdesivir should have been apparent in both arms, not just one.

By consistently allowing poorly designed trials to make their way in to prestigious journals – JAMA is the third highest rated medicine journal in the world – the medical fraternity is doing itself a great disservice. Research can only be considered reliable when it is scientifically sound and can withstand the scrutiny of rigorous peer review. Once trust in science is eroded, the after effects will be felt long after the pandemic has abated."


https://science.thewire.in/the-sciences/remde...d-science/

https://jamanetwork.com/journals/jama/fullarticle/2769870
https://jamanetwork.com/journals/jama/fullarticle/2768397

Regeneron's antibody treatment is still under review. Regeneron has tightly controlled the little data that has been released. Regeneron claims treatment given early can reduce the viral load and reduce "medically supervised visits". I can find no data on mortality, complications, reduced ventilator or oxygen usage.
The best summary I could find of the data is below describing both Regeneron's antibody and Lily's Bamlanivimab.

".. the monoclonal antibody products I'll be discussing have had studies that have not shown benefit or have been associated with worse outcomes for hospitalized patients, especially those on high-flow oxygen or in the intensive care unit (ICU)."

"This kind of strategy for early treatment is going to be a minor contribution from a prevention standpoint before we have widespread, effective vaccines. Studies remain in progress where it might have a larger role (although a very expensive one) in preventing disease in patients who might be at [higher] risk — especially, for example, in congregate living facilities or nursing facilities. Unfortunately, we will need to wait for data to see if this is effective.

So, we have some newer therapies. Nothing is a home run... "

https://www.medscape.com/viewarticle/941830

New data released suggested a use for monoclonal antibodies and Remdesivir for preventative care.

https://www.medscape.com/viewarticle/945136#vp_2

GLTA Farrell



Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 229

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 211

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 182

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 187

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 304

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Withdraw from Firms Vulnerable to AI Disruption

Updated Category News Views 397

The Growing Concern Over AI Disruption In recent times, there has been increasing unease among investors related to how artificial intelligence (AI) could potentially disrupt numerous industries. This anxiety has led to significant withdrawals from companies viewed as susceptible to these technological advancements. Identifying At-Risk Companies Firms such as Adobe Inc....

Continue Reading
Community Impact: Sunrise Maids Enhances Lives in Katy Area

Updated Category News Views 152

Sunrise Maids: Committed to Community Enrichment Sunrise Maids is not just another cleaning service; it embodies the spirit of giving back in Katy with its exceptional maid services. This locally operated company is well-known for its unwavering commitment to maintaining clean and healthy living spaces. But what sets Sunrise Maids apart is their strong dedication to...

Continue Reading
Air France-KLM Launches New Liquidity Contract with Rothschild

Updated Category News Views 188

Introduction of a New Liquidity Contract Air France-KLM is excited to announce its latest initiative to enhance market performance through a new liquidity contract. This partnership with Rothschild Martin Maurel is designed to fortify the trading environment for its shares, aligning with regulatory frameworks and practices. Details of the Liquidity Agreement The liquidity...

Continue Reading
Valeo's H1 2025 Performance: Insights and Financial Highlights

Updated Category News Views 499

Overview of Valeo's H1 2025 Financial Results Valeo has exhibited a notable improvement in its profitability metrics during the first half of 2025. The company's operating margin reached 4.5%, while their free cash flow stood at an impressive 252 million euros. This performance aligns well with Valeo's overall goals for profitability and cash generation for the year....

Continue Reading
Chinese Financial Landscape Shifts as Central Bank Takes Action

Updated Category News Views 90

Chinese Stocks Surge After Central Bank's Stimulus Measures Chinese stocks saw a notable increase after an unexpected announcement from the central bank, which introduced vital monetary stimulus measures. This decisive action is designed to revive the slowing economy and restore confidence among investors. Monetary Easing: A Comprehensive Approach The central bank...

Continue Reading